NZ329656A - Oxazole and thiazoles derivatives containing a fibrinogen receptor antagonist template - Google Patents
Oxazole and thiazoles derivatives containing a fibrinogen receptor antagonist templateInfo
- Publication number
- NZ329656A NZ329656A NZ329656A NZ32965698A NZ329656A NZ 329656 A NZ329656 A NZ 329656A NZ 329656 A NZ329656 A NZ 329656A NZ 32965698 A NZ32965698 A NZ 32965698A NZ 329656 A NZ329656 A NZ 329656A
- Authority
- NZ
- New Zealand
- Prior art keywords
- receptor antagonist
- fibrinogen receptor
- formula
- oxazole
- antagonist template
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compounds are disclosed which are vitronectin receptor antagonists useful in the treatment of inflammation, cancer, cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis. These compounds comprise a fibrinogen receptor antagonist template linked to a heterocyclic moiety. The compound claimed according to formula (II). G is S or O; W is CHRga-U-CHRgb-V- or formula (IV) A is a fibrinogen receptor antagonist template (illustrated according to formula (a) to (i) Wherein R1 and R1, are R* or R, or together are =O; R2 and R2, are R* or R, or together are =O; R3 and R3, are R* or R, or together are =O; R4 and R4, are R* or R, or together are =O; R5 and R5, are R* or R, or together are =O; R is at least one substituent chosen from the group of R7, or Q-C1-4alkyl, Q-C1-4alkenyl, Q-C2-4alkynyl, optional substituted by one or more =O, R11 or R7; and R* is H, Q-C1-6alkyl, Q-C1-6oxoalkyl, Q-C2-6oxoalkyl, Q-C2-6oxoalkenyl, Q-C3-4oxoalkynyl, Q-C2-4oxoalkynyl, Q-C3-6oxoalkynyl, Ar or Het, optional substituted by one or more R11
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26769594A | 1994-06-29 | 1994-06-29 | |
US42893395A | 1995-04-25 | 1995-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ329656A true NZ329656A (en) | 2000-01-28 |
Family
ID=26952569
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ290008A NZ290008A (en) | 1994-06-29 | 1995-06-29 | Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle |
NZ329656A NZ329656A (en) | 1994-06-29 | 1998-01-28 | Oxazole and thiazoles derivatives containing a fibrinogen receptor antagonist template |
NZ329822A NZ329822A (en) | 1994-06-29 | 1998-02-23 | Pyrrole derivatives bound to a fibrinogen receptor antagonist template |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ290008A NZ290008A (en) | 1994-06-29 | 1995-06-29 | Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ329822A NZ329822A (en) | 1994-06-29 | 1998-02-23 | Pyrrole derivatives bound to a fibrinogen receptor antagonist template |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0767792A4 (en) |
JP (1) | JPH10504808A (en) |
CN (1) | CN1156995A (en) |
AU (1) | AU702661B2 (en) |
BR (1) | BR9508178A (en) |
CA (1) | CA2193966A1 (en) |
CZ (1) | CZ382496A3 (en) |
HU (1) | HUT76344A (en) |
MX (1) | MX9700041A (en) |
NO (1) | NO965608L (en) |
NZ (3) | NZ290008A (en) |
PL (1) | PL318199A1 (en) |
WO (1) | WO1996000730A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100423A (en) * | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
CN1085980C (en) * | 1995-08-30 | 2002-06-05 | G·D·瑟尔公司 | meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
ES2171768T3 (en) | 1996-03-20 | 2002-09-16 | Hoechst Ag | OSEA RESORTION INHIBITORS AND VITRONECTINE RECEPTORS ANTAGONISTS. |
DE19629817A1 (en) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
DE19629816A1 (en) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
UA60311C2 (en) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Vitronectin receptor antagonists |
EP0946180A4 (en) * | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | Method for stimulating bone formation |
DE19653647A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
DE19653645A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin receptor antagonists, their preparation and their use |
US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
DE19653646A1 (en) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituted purine derivatives, processes for their preparation, agents containing them and their use |
US6214834B1 (en) | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
EP1007051A4 (en) * | 1997-08-04 | 2001-08-29 | Smithkline Beecham Corp | Integrin receptor antagonists |
US6313119B1 (en) | 1998-01-23 | 2001-11-06 | Adventis Pharma Deutschland Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
AU3213799A (en) * | 1998-04-01 | 1999-10-18 | Du Pont Pharmaceuticals Company | Integrin antagonists |
US6228985B1 (en) | 1998-05-21 | 2001-05-08 | Schering Corporation | Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents |
US6852725B1 (en) * | 1998-06-12 | 2005-02-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. | Imidazolyl derivatives |
CA2339666A1 (en) * | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
DE19842415A1 (en) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US6204282B1 (en) | 1998-11-30 | 2001-03-20 | Schering Corporation | Benzimidazole compounds that are vitronectin receptor antagonists |
CN1161340C (en) * | 1998-11-30 | 2004-08-11 | 先灵公司 | Benzimidazole compounds that are vitronectin receptor antagonists |
US6339083B1 (en) | 1998-12-14 | 2002-01-15 | Bayer Aktiengesellschaft | Multiheterocyclic pharmAceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
CA2349333A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
WO2000046215A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
US6281237B1 (en) | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
DE60014339T8 (en) * | 1999-04-02 | 2006-04-27 | Neurogen Corp., Branford | ARYL AND HETEROARYL-CONDENSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAA RECEPTORS |
JP2002541145A (en) * | 1999-04-02 | 2002-12-03 | ニューロゲン コーポレイション | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: Bradykinin B2 receptor selective modulators |
US6358949B1 (en) | 1999-04-02 | 2002-03-19 | Neurogen Corporation | Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors |
US6627624B1 (en) | 1999-04-02 | 2003-09-30 | Neurogen Corporation | Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
CN1208323C (en) | 1999-04-06 | 2005-06-29 | 三共株式会社 | Alpha-substituted carboxylic acid derivatives |
CO5180550A1 (en) | 1999-04-19 | 2002-07-30 | Smithkline Beecham Corp | FAB I INHIBITORS |
CO5370679A1 (en) | 1999-06-01 | 2004-02-27 | Smithkline Beecham Corp | FAB INHIBITORS 1 |
US6730684B1 (en) | 1999-10-08 | 2004-05-04 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
US6762201B1 (en) | 1999-10-08 | 2004-07-13 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
CA2387016C (en) | 1999-10-08 | 2010-09-28 | William H. Miller | Acrylamide derivatives as fab i inhibitors |
TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
WO2001056995A1 (en) * | 2000-01-18 | 2001-08-09 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
FR2806082B1 (en) * | 2000-03-07 | 2002-05-17 | Adir | NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2001090186A1 (en) | 2000-05-26 | 2001-11-29 | Glaxo Group Limited | Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof |
US7566734B2 (en) | 2000-08-01 | 2009-07-28 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Imidazolyl derivatives |
JP2004521079A (en) * | 2000-08-29 | 2004-07-15 | ファルマシア・コーポレーション | Compounds containing bicyclic ring systems useful as alpha vbeta3 antagonists |
FR2822463B1 (en) | 2001-03-21 | 2004-07-30 | Lipha | BICYCLIC GUANIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
WO2003088897A2 (en) | 2001-04-06 | 2003-10-30 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
RU2316337C2 (en) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | Combined therapy by using antiangiogenic agents and tnf-alpha |
US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
FR2829765A1 (en) * | 2001-09-14 | 2003-03-21 | Lipha | Use of new and known benzimidazolyl alkoxyaryl alkanoic acid derivatives for treating pathologies associated with insulin resistance or hyperglycemia |
WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
FR2847254B1 (en) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM |
PE20040804A1 (en) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | CARBOXAMID DERIVATIVES AS INHIBITORS OF THE Xa FACTOR |
FR2870541B1 (en) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
EP1973569B1 (en) | 2006-01-18 | 2013-05-22 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
EP2054422B1 (en) | 2006-07-20 | 2017-06-14 | Debiopharm International SA | Acrylamide derivatives as fab i inhibitors |
PL2101805T3 (en) | 2007-01-18 | 2013-04-30 | Merck Patent Gmbh | Integrin ligands for use in treating cancer |
EP3255045A1 (en) | 2007-02-16 | 2017-12-13 | Debiopharm International SA | Salts, prodrugs and polymorphs of fab i inhibitors |
AU2008321770B2 (en) * | 2007-11-16 | 2012-09-06 | Ube Industries, Ltd. | Benzazepinone compound |
WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
JP5572996B2 (en) * | 2009-05-15 | 2014-08-20 | 宇部興産株式会社 | Medicine containing benzazepinone compound as active ingredient |
WO2010136168A2 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
SG10201505022WA (en) | 2010-06-24 | 2015-07-30 | Gilead Sciences Inc | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
AU2012358805B2 (en) | 2011-12-22 | 2017-07-20 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
DK2838900T3 (en) | 2012-04-17 | 2019-10-14 | Gilead Sciences Inc | RELATIONS AND PROCEDURES FOR ANTIVIRAL TREATMENT |
JP6085026B2 (en) | 2012-06-19 | 2017-02-22 | デビオファーム インターナショナル エスエーDebiopharm International Sa | (E) -N-methyl-N-((3-methylbenzofuran-2-yl) methyl) -3- (7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl ) Prodrug derivatives of acrylamide |
WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
US10751351B2 (en) | 2016-02-26 | 2020-08-25 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
CN108707116B (en) * | 2018-07-05 | 2021-11-30 | 华侨大学 | 2-alkyl substituted benzimidazole derivative and preparation method thereof |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR71915B (en) * | 1979-11-27 | 1983-08-16 | Pfizer | |
US4556660A (en) * | 1982-07-12 | 1985-12-03 | Janssen Pharmaceutica N.V. | N-(Bicyclic heterocyclyl)-4-piperidinamines |
GB8316645D0 (en) * | 1983-06-18 | 1983-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
FR2643903A1 (en) * | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS |
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
RU1836357C (en) * | 1990-07-23 | 1993-08-23 | Др.Карл Томэ ГмбХ | Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine |
ZA924760B (en) * | 1991-06-28 | 1993-03-31 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
CN1041921C (en) * | 1992-12-21 | 1999-02-03 | 史密丝克莱恩比彻姆公司 | Bicyclic fibrinogen antagonists |
DE69418035T2 (en) * | 1993-01-15 | 1999-08-12 | Agouron Pharma | HIV PROTEAS INHIBITORS |
US5300668A (en) * | 1993-03-10 | 1994-04-05 | Pfizer Inc. | Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates |
-
1995
- 1995-06-29 JP JP8503462A patent/JPH10504808A/en not_active Ceased
- 1995-06-29 PL PL95318199A patent/PL318199A1/en unknown
- 1995-06-29 CZ CZ963824A patent/CZ382496A3/en unknown
- 1995-06-29 BR BR9508178A patent/BR9508178A/en not_active Application Discontinuation
- 1995-06-29 WO PCT/US1995/008306 patent/WO1996000730A1/en not_active Application Discontinuation
- 1995-06-29 MX MX9700041A patent/MX9700041A/en unknown
- 1995-06-29 EP EP95926152A patent/EP0767792A4/en not_active Withdrawn
- 1995-06-29 HU HU9603525A patent/HUT76344A/en unknown
- 1995-06-29 CN CN95194853A patent/CN1156995A/en active Pending
- 1995-06-29 NZ NZ290008A patent/NZ290008A/en unknown
- 1995-06-29 AU AU30010/95A patent/AU702661B2/en not_active Ceased
- 1995-06-29 CA CA002193966A patent/CA2193966A1/en not_active Abandoned
-
1996
- 1996-12-27 NO NO965608A patent/NO965608L/en unknown
-
1998
- 1998-01-28 NZ NZ329656A patent/NZ329656A/en unknown
- 1998-02-23 NZ NZ329822A patent/NZ329822A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2193966A1 (en) | 1996-01-11 |
CN1156995A (en) | 1997-08-13 |
JPH10504808A (en) | 1998-05-12 |
NO965608D0 (en) | 1996-12-27 |
HUT76344A (en) | 1997-08-28 |
WO1996000730A1 (en) | 1996-01-11 |
NZ329822A (en) | 2000-02-28 |
AU3001095A (en) | 1996-01-25 |
EP0767792A1 (en) | 1997-04-16 |
PL318199A1 (en) | 1997-05-26 |
AU702661B2 (en) | 1999-02-25 |
BR9508178A (en) | 1997-11-18 |
HU9603525D0 (en) | 1997-02-28 |
MX9700041A (en) | 1997-04-30 |
NZ290008A (en) | 1998-08-26 |
EP0767792A4 (en) | 2002-11-20 |
CZ382496A3 (en) | 1997-12-17 |
NO965608L (en) | 1997-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ329656A (en) | Oxazole and thiazoles derivatives containing a fibrinogen receptor antagonist template | |
GEP20053421B (en) | Substituted Pyrazoles As P38 Kinase Inhibitors, Method for Their Production and Pharmaceutical Compositions Containing Them | |
DE69328975D1 (en) | AMINOMETHYLENE SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALSO SUBSTANCE P ANTAGONISTS | |
NZ510435A (en) | Arylsulfonanilide ureas and pharmaceutical use | |
IL151626A0 (en) | Quinazoline compounds | |
SI0773943T1 (en) | Compounds useful as antiproliferative agents and garft inhibitors | |
DE60023318D1 (en) | Heteropolycyl compounds and their use as antagonists of metabotropic glutamate receptors | |
MY119800A (en) | Pyridine derivatives | |
HUT62893A (en) | Process for producing substituted pyrimidine derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
CA2340999A1 (en) | 5-arylindole derivatives | |
CA2252907A1 (en) | Novel 2,3 disubstituted-4(3h)-quinazolinones | |
DE3781080D1 (en) | 2-SUBSTITUTED-E-CONDENSED (1,2,4) TRIAZOLO- (1,5-C) PYRIMIDINE, PHARMACEUTICAL PREPARATIONS AND THEIR USE. | |
HUT53099A (en) | Process for producing new tetrahydrobenzimidazole derivatives and pharmaceutical compositions comprising such compounds | |
ES2078356T3 (en) | DERIVATIVES OF PIRROLIDINE AND PIPERIDINE. | |
ATE259376T1 (en) | HETEROCYCLIC COMPOUNDS, THEIR INTERMEDIATE PRODUCTS AND ELASTASE INHIBITORS | |
TW223016B (en) | ||
TW360650B (en) | Pyridin-2-ylmethyloxy-pyridin-5-ylcarbamoyl-indoline derivatives, a process for the preparation thereof, and a pharmaceutical composition comprising them | |
DE69230498D1 (en) | 2-pyrazinylethylamine derivatives and their use as medicines. | |
DE502004007387D1 (en) | TRIAZONE COMPOUNDS AND ITS THERAPEUTIC USE | |
DE69324910T2 (en) | TRIAZOLOPYRIMIDINE DERIVATIVES AS ANGIOTENSIN-II RECEPTOR ANTAGONISTS | |
DK1072601T3 (en) | 4-Arylpiperidine derivatives for the treatment of pruritus | |
DK1049670T3 (en) | Azetidine carboxamide derivatives for the treatment of CNS disorders | |
ES2156617T3 (en) | DERIVATIVES OF 1,9-DIAZABICICLO (4.3.0) NONA-3,8-DIENO. |